Atricure Intrinsic Value Calculator – AtriCure Jumps 7.5% Despite Uncertainty in Earnings Estimates For 2023.
March 28, 2023
Trending News ☀️
ATRICURE ($NASDAQ:ATRC): This recent surge in stock price could indicate a positive sign for the company’s future prospects. Despite this, market analysts are uncertain of the company’s earnings estimates for 2023 due to the turbulent economic environment. It is unclear at this stage if the stock surge will be sustainable or if it is a short term trend. Despite the uncertain economic climate, AtriCure is still committed to providing innovative medical solutions to its customers around the world. The company is focused on investing in research and development to improve its technology, expand its product line, and increase efficiency in order to create value for shareholders.
As the global healthcare industry continues to expand, AtriCure is well positioned to capitalize on this growth and continue to provide its customers with high quality products and services. While the uncertainty surrounding earnings estimates for 2023 remains a concern, investors should still keep an eye on AtriCure’s share price and trends in order to determine if this recent jump in stock price is sustainable. With the right strategies in place and a focus on innovation and growth, AtriCure could be a solid long-term investment.
Price History
On Monday, AtriCure Inc. (ATRICURE) stock opened at $41.1 and closed at $40.4, down by 0.9% from previous closing price of 40.8. Despite this, there is still a sense of caution among investors as the earnings estimates remain uncertain. Analysts are monitoring news on the company closely and any new developments could affect the stock price in the near term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Atricure. More…
| Total Revenues | Net Income | Net Margin |
| 330.38 | -46.47 | -14.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Atricure. More…
| Operations | Investing | Financing |
| -22.14 | 44.01 | -7.06 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Atricure. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 585.45 | 128.69 | 9.81 |
Key Ratios Snapshot
Some of the financial key ratios for Atricure are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.7% | – | -12.5% |
| FCF Margin | ROE | ROA |
| -11.8% | -5.7% | -4.4% |
Analysis – Atricure Intrinsic Value Calculator
At GoodWhale, we recently performed an analysis of ATRICURE‘s wellbeing. Our proprietary Valuation Line calculated the fair value of ATRICURE share to be approximately $68.4. However, ATRICURE stock is currently being traded at $40.4, which means it is undervalued by 40.9%. Based on our analysis, we believe investors should consider taking a closer look at this stock, as it may present a good opportunity to buy at a discounted price. More…
Peers
The company was founded in 2000 and is headquartered in Mason, Ohio. AtriCure‘s competitors include Abiomed Inc, LeMaitre Vascular Inc, and Nevro Corp. These companies also provide medical devices and services for the treatment of Afib and other cardiovascular conditions.
– Abiomed Inc ($NASDAQ:ABMD)
Abiomed Inc. is a medical device company that develops and manufactures products to treat congestive heart failure and acute cardiac conditions. The company’s product portfolio includes implantable cardioverter defibrillators, left ventricular assist devices, and heart pumps. Abiomed’s products are used by hospitals and clinics around the world. The company has a market capitalization of $16.86 billion and a return on equity of 10.55%. Abiomed is headquartered in Danvers, Massachusetts.
– LeMaitre Vascular Inc ($NASDAQ:LMAT)
LeMaitre Vascular Inc is a medical device company that specializes in the manufacturing of devices and implants for the treatment of peripheral vascular diseases. The company has a market capitalization of 984.38 million as of 2022 and a return on equity of 6.77%. The company’s products are used by surgeons to treat a variety of vascular conditions, including arterial and venous diseases.
– Nevro Corp ($NYSE:NVRO)
As of 2022, Nevro Corp has a market cap of 1.44B and a Return on Equity of -34.12%. The company is a medical device company that develops and commercializes proprietary neuromodulation solutions for the treatment of chronic pain.
Summary
Investing in AtriCure, Inc., a medical device company focused on the development of innovative, minimally invasive treatment options for persistent and long-standing atrial fibrillation (AFib), is becoming more attractive for investors. The news and sentiment from the market so far have been mostly positive, and investors are optimistic about the company’s future potential. AtriCure’s products address serious medical conditions and demonstrate significant clinical benefit, which should support long-term revenue growth. The company has also been actively working on expanding its product portfolio to reach new markets.
This focus on innovation and customer needs is likely to help the company generate an even greater growth rate in the future. Thus, investors should remain optimistic on AtriCure’s prospects and consider investing in it while taking into account their own individual risk tolerance.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
